For the quarter ending 2025-09-30, ACRS has $175,534K in assets. $55,434K in debts. $25,256K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Prepaid expenses and other current assets | - | 4,202 | ||
| Cash and cash equivalents | 25,256 | 25,402 | ||
| Short-term marketable securities | 70,656 | 74,404 | ||
| Accounts receivable, net | - | 194 | ||
| Accounts receivable, prepaid expenses and other current assets | 4,680 | - | ||
| Total current assets | 100,592 | 104,202 | ||
| Marketable securities | 71,297 | 81,084 | ||
| Property and equipment, net | 811 | 868 | ||
| Other assets | 2,834 | 2,993 | ||
| Total assets | 175,534 | 189,147 | ||
| Accounts payable | 9,187 | 8,797 | ||
| Accrued expenses | 9,784 | 11,411 | ||
| Deferred income | 3,925 | 3,914 | ||
| Other current liabilities | 2,735 | 2,717 | ||
| Total current liabilities | 25,631 | 26,839 | ||
| Other liabilities | 1,711 | 1,851 | ||
| Deferred income, net of current portion | 17,492 | 18,218 | ||
| Contingent consideration | 10,600 | 10,500 | ||
| Total liabilities | 55,434 | 57,408 | ||
| Common stock, 0.00001 par value 400,000,000 and 200,000,000 shares authorized at september 30, 2025 and december 31, 2024, respectively 108,342,592 and 107,850,124 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 1 | 1 | ||
| Additional paid-in capital | 1,067,491 | 1,064,631 | ||
| Accumulated other comprehensive income | 597 | 482 | ||
| Accumulated deficit | -947,989 | -933,375 | ||
| Total stockholders' equity | 120,100 | 131,739 | ||
| Total liabilities and stockholders' equity | 175,534 | 189,147 | ||
Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS)